BACKGROUND: A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS: Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS: Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS: Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.
BACKGROUND: A large amount of interindividual variability exists in the occurrence of symptoms in patients receiving chemotherapy (CTX). The purposes of the current study, which was performed in a sample of 582 oncology outpatients who were receiving CTX, were to identify subgroups of patients based on their distinct experiences with 25 commonly occurring symptoms and to identify demographic and clinical characteristics associated with subgroup membership. In addition, differences in quality of life outcomes were evaluated. METHODS: Oncology outpatients with breast, gastrointestinal, gynecological, or lung cancer completed the Memorial Symptom Assessment Scale before their next cycle of CTX. Latent class analysis was used to identify subgroups of patients with distinct symptom experiences. RESULTS: Three distinct subgroups of patients were identified (ie, 36.1% in Low class; 50.0% in Moderate class, and 13.9% in All High class). Patients in the All High class were significantly younger and more likely to be female and nonwhite, and had lower levels of social support, lower socioeconomic status, poorer functional status, and a higher level of comorbidity. CONCLUSIONS: Findings from the current study support the clinical observation that some oncology patients experience a differentially higher symptom burden during CTX. These high-risk patients experience significant decrements in quality of life.
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; N Coyle; T Smart-Curley; N Kemeny; L Norton; W Hoskins Journal: Qual Life Res Date: 1994-06 Impact factor: 4.147
Authors: Kimberly E Alexander; Suzanne Chambers; Amanda B Spurdle; Jyotsna Batra; Felicity Lose; Tracy A O'Mara; Robert A Gardiner; Joanne F Aitken; Judith A Clements; Mary-Anne Kedda; Monika Janda Journal: Qual Life Res Date: 2015-02-28 Impact factor: 4.147
Authors: Christine Miaskowski; Melisa L Wong; Bruce A Cooper; Judy Mastick; Steven M Paul; Katherine Possin; Michael Steinman; Janine Cataldo; Laura B Dunn; Christine Ritchie Journal: J Pain Symptom Manage Date: 2017-07-15 Impact factor: 3.612
Authors: Komal Singh; Kord M Kober; Steven M Paul; Marilyn Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2019-08-19 Impact factor: 3.603
Authors: Maria Tejada; Carol Viele; Kord M Kober; Bruce A Cooper; Steven M Paul; Laura B Dunn; Marilyn J Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Kate Oppegaard; Carolyn S Harris; Joosun Shin; Steven M Paul; Bruce A Cooper; Jon D Levine; Yvette P Conley; Marilyn Hammer; Frances Cartwright; Fay Wright; Laura Dunn; Kord M Kober; Christine Miaskowski Journal: Support Care Cancer Date: 2021-06-26 Impact factor: 3.603
Authors: Melisa L Wong; Steven M Paul; Judy Mastick; Christine Ritchie; Michael A Steinman; Louise C Walter; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-23 Impact factor: 3.612
Authors: Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2020-08-03 Impact factor: 2.398
Authors: Nikoloas Papachristou; Payam Barnaghi; Bruce A Cooper; Xiao Hu; Roma Maguire; Kathi Apostolidis; Jo Armes; Yvette P Conley; Marilyn Hammer; Stylianos Katsaragakis; Kord M Kober; Jon D Levine; Lisa McCann; Elisabeth Patiraki; Steven M Paul; Emma Ream; Fay Wright; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-08-30 Impact factor: 3.612